Massachusetts Biotechnology Council: Survey Finds U.S. Biotechs Advancing Treatments for Rare and Serious Diseases Want to Run Clinical Trials in U.S. But Regulatory Hurdles are Sending Them Abroad
August 13, 2026
August 13, 2026
CAMBRIDGE, Massachusetts, Aug. 13 -- The Massachusetts Biotechnology Council issued the following news:
* * *
Survey Finds U.S. Biotechs Advancing Treatments for Rare and Serious Diseases Want to Run Clinical Trials in U.S. but Regulatory Hurdles are Sending Them Abroad
76% of surveyed companies select U.S. as runaway first choice for first-in-human (FIH) trials but 72% are hesitant to run FIH trials in the U.S. under FDA's historical framework, pushin . . .
* * *
Survey Finds U.S. Biotechs Advancing Treatments for Rare and Serious Diseases Want to Run Clinical Trials in U.S. but Regulatory Hurdles are Sending Them Abroad
76% of surveyed companies select U.S. as runaway first choice for first-in-human (FIH) trials but 72% are hesitant to run FIH trials in the U.S. under FDA's historical framework, pushin . . .